DE2246613A1 - Mixed salts of para-chlorophenoxyisobutyric acid and - nicotinic acid - with combined activities of the acids - Google Patents

Mixed salts of para-chlorophenoxyisobutyric acid and - nicotinic acid - with combined activities of the acids

Info

Publication number
DE2246613A1
DE2246613A1 DE19722246613 DE2246613A DE2246613A1 DE 2246613 A1 DE2246613 A1 DE 2246613A1 DE 19722246613 DE19722246613 DE 19722246613 DE 2246613 A DE2246613 A DE 2246613A DE 2246613 A1 DE2246613 A1 DE 2246613A1
Authority
DE
Germany
Prior art keywords
acid
chlorophenoxyisobutyric
nicotinic acid
mixed salts
para
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19722246613
Other languages
German (de)
Inventor
Wilhelm Dr Hurka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE2246613A1 publication Critical patent/DE2246613A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New mixed salts of Mg or Al with p-chlorophenoxyisobutyric acid (I) and nicotinic acid (II) are prepd. by treating an equimolar mixt. of (I) and (II) with a Mg or Al salt and H2O. The salts have the combined activities of (I) and (II) and can be used to treat arteriosclerosis, cerebrovascular disorders and coronary vascular disorders, and for increasing peripheral circulation.

Description

Verfahren zur Herstellung neuer gemischter Salze von Magnesium oder Aluminium mit p-Chlorphenoxyisobuttersäure und Nicotinsäure Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung neuer gemischter Salze von Magnesium oder Aluminiurn mit p-Chlorphenoxyisobuttersäure und Nicotinsäure. Diese Salze haben die allgemeine Formel worin M für Magnesium oder Aluminium steht.Process for the preparation of new mixed salts of magnesium or aluminum with p-chlorophenoxyisobutyric acid and nicotinic acid The present invention relates to a process for the preparation of new mixed salts of magnesium or aluminum with p-chlorophenoxyisobutyric acid and nicotinic acid. These salts have the general formula where M is magnesium or aluminum.

Diese Salze finden als Pharmazeutiea Verwendung, wobei die beiden Komponenten, die in der Verbindung enthalten sind, die p-Chlorphenoxyisobuttersäure und die Nicotinsäure, zusammenwirken und sich ergänzen. These salts are used as pharmaceuticals, with the two Components contained in the compound, the p-chlorophenoxyisobutyric acid and the Nicotinic acid, interact and complement each other.

p-Chlorphenoxyisobuttersäure dient zur Bekämpfung der Arteriosklerose. Es wird die Blutplättchenaggregation verhindert, so dai3 z.B. auch nach fetter Nahrung die Viskosität des Blutes relativ niedrig bleibt, Weiters verhindert diese Substanz die Bildung von körpereigenem Cholesterin, bestehende Cholesterinablagerungen werden (besonders im Auge) abgebaut. Die Polige dieser-Wirkirng ist eine größere Elastizität der Gefäße. p-Chlorophenoxyisobutyric acid is used to combat arteriosclerosis. Platelet aggregation is prevented, so that, for example, also after fatty food the viscosity of the blood remains relatively low, furthermore this substance prevents it the formation of endogenous cholesterol, existing cholesterol deposits become (especially in the eye) degraded. The pole of this effect is a greater elasticity the vessels.

Die Nicotinsäure senkt den Triglycerid-Spiegel und Phospholinidspiegel im Blut. Die peripheren Blutgefäße werden durch die Nicotinsäure erweitert, Eine Kombination dieser beiden Substanzen in einer Verbindung ergibt einen Wirkstoff, der die Wirkung der beiden Komponenten, nämlich p-Chlorphenoxyisobuttersäure und Nicotinsäure, in sich ve;'eint0 Dieser Wirkstoff ist geeignet für die Behandlung von Arterosklerose, cerebrobaseularen Störungen, coronarvaskularen Störungen und für eine Erhöhung der peripheren Durchblutung. The nicotinic acid lowers the triglyceride level and phospholinide level in blood. The peripheral blood vessels are dilated by the nicotinic acid, a Combination of these two substances in one compound results in an active ingredient, which the effect of the two components, namely p-chlorophenoxyisobutyric acid and Nicotinic acid, in itself ve; 'eint0 This active ingredient is suitable for treatment of atherosclerosis, cerebrobaseular disorders, coronary vascular disorders and for an increase in peripheral blood flow.

Die Vorteile, die durch den erfindungsgemäßen Vorschlag, die beiden Komponenten in Form ihrer gemischten Salze einzusetzen, gegenüber der Anwendung einer Mischung aus den Säuresalzen liegt darin, daß weniger Magnesium in den Körper gebracht wird, wodurch eine geringere Einlagerung von Magnesium im Knochensystem resultiert0 Das erfindungsgemäße Verfahren besteht darin, daß man äquimolare Mengen an p-Chlorphenoxyisobuttersäure und Nicotinsäure mit einem Magnesium- oder Aluminiumsalz und Wasser versetzt und das Salz isoliert. The advantages brought about by the proposal according to the invention, the two To use components in the form of their mixed salts, compared to the application A mixture of the acid salts means that there is less magnesium in the body is brought about, whereby a lower deposition of magnesium in the bone system results0 The process according to the invention consists in using equimolar amounts of p-chlorophenoxyisobutyric acid and nicotinic acid with a magnesium or aluminum salt and water are added and the salt is isolated.

Beispiel 1: 1 g Nicotinsäure (0,008 Mol) und 1,73 g p-chlorphenoxyisobuttersäure (0,008 Mol) werden mit lo ml Wasser versetzt, 0,32 g Magnesiumoxyd in lo ml Wasser werden zugegeben und bis zur Lösung der Komponenten gerührt. Eine verbleibende schwache Trübung wird abfiltriert, das Filtrat wird im Vakuum auf dem Wasserbad bis zur Trockne eingeengt.Example 1: 1 g of nicotinic acid (0.008 mol) and 1.73 g of p-chlorophenoxyisobutyric acid (0.008 mol) are mixed with lo ml of water, 0.32 g of magnesium oxide in lo ml of water are added and stirred until the components are dissolved. One remaining weak The turbidity is filtered off, the filtrate is dried in vacuo on a water bath constricted.

Man erhält ein gelblichweißes Pulver vom FP 280 - 285 (Zersetzung). Ausbeute 98 %o Beispiel 2: Zu einer heißen Lösung von 1 g Nicotinsäure (0,0081 Mol), 1,73 g p-chlorphenoxyisobuttersäure (0,0081 Mol) und 1,06 g Natriumcarbonat in 60 ml Wasser fügt man eine Lösung von 1,74 g Aluminiumchlorid mit 6 Mol Kristallwasser in 15 ml Wasser. Es entsteht ein weißer Niederschlag.A yellowish white powder of FP 280-285 (decomposition) is obtained. Yield 98% o Example 2: To a hot solution of 1 g of nicotinic acid (0.0081 mol), 1.73 g of p-chlorophenoxyisobutyric acid (0.0081 mol) and 1.06 g of sodium carbonate in 60 ml of water is added to a solution of 1.74 g of aluminum chloride with 6 mol of water of crystallization in 15 ml of water. A white precipitate forms.

Man läßt bei Zimmertemperatur 12 Stunden stehen und saugt den Niederschlag ab. Nach Trocknung im Vakuumtrockenschrank bei 30° und 12 mm Quecksilber erhält man ein weißes Pulver vom FP 2590 - 2610 (Zersetzung). The mixture is left to stand at room temperature for 12 hours and the precipitate is sucked off away. After drying in a vacuum drying cabinet at 30 ° and 12 mm of mercury a white powder from FP 2590-2610 (decomposition).

Ausbeute 92 %oYield 92% o

Claims (1)

Patentanspruch: Verfahren zur Herstellung neuer gemischter Salze von Magnesium oder Aluminium mit p-Chlorphenoxyisobuttersäure und Nicotinsäure, dadurch gekennzeichnet, daß man äquimolare Mengen an p-Chlorphenoxyisobuttersäure und Nicotinsäure mit einem Magnesium- oder Aluminiumsalz und Wasser versetzt und das Salz isoliert. Claim: Process for the production of new mixed salts of magnesium or aluminum with p-chlorophenoxyisobutyric acid and nicotinic acid, characterized in that equimolar amounts of p-chlorophenoxyisobutyric acid and nicotinic acid is mixed with a magnesium or aluminum salt and water and the salt isolates.
DE19722246613 1971-10-05 1972-09-22 Mixed salts of para-chlorophenoxyisobutyric acid and - nicotinic acid - with combined activities of the acids Pending DE2246613A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT860671 1971-10-05

Publications (1)

Publication Number Publication Date
DE2246613A1 true DE2246613A1 (en) 1973-04-12

Family

ID=3606982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19722246613 Pending DE2246613A1 (en) 1971-10-05 1972-09-22 Mixed salts of para-chlorophenoxyisobutyric acid and - nicotinic acid - with combined activities of the acids

Country Status (1)

Country Link
DE (1) DE2246613A1 (en)

Similar Documents

Publication Publication Date Title
DE2246613A1 (en) Mixed salts of para-chlorophenoxyisobutyric acid and - nicotinic acid - with combined activities of the acids
DE2036935A1 (en) Process for the production of isoniazid derivatives
DE1493618A1 (en) Coumarin derivatives and a process for their preparation
DE405017C (en) Process for the preparation of complex silver compounds of sulfur-containing carboxylic acids
DE488891C (en) Process for the preparation of N-substituted arsenobenzimidazolones
DE601995C (en) Process for the preparation of complex antimony compounds
CH155688A (en) Process for the preparation of a water-soluble antimony salt.
AT79103B (en) Process for the production of new isovaleric acid preparations.
DE2433889C2 (en) Process for the production of pure allcls-cyclopentane-1,2,3,4-tetracarboxylic acid or its salts
DE1620675C (en) S-Benzoyloxymethylthiamines and processes for their preparation
AT146484B (en) Process for the purification of raw phosphoric acid.
AT222807B (en) Process for the production of a therapeutically effective product
DE604070C (en) Process for the production of neutral soluble complex salts of trivalent antimony
DE894994C (en) Process for the production of aliphatic mercury ketone compounds
DE351384C (en) Production of a colloidal iron solution with a neutral or weakly alkaline reaction
CH403798A (en) Process for the preparation of a medicament containing amprotropin
DE619348C (en) Process for the production of pure diacetyl from wood vinegar or other mixtures containing diacetyl
DE650221C (en) Process for the preparation of water-soluble complex alkali rhodium nitrites
AT106981B (en) Process for the production of acid-free, pure, resinous condensation products from phenols and aldehydes.
AT217022B (en) Process for the production of the new cysteamine orotate
DE554008C (en) Process for the production of the co-zymase
DE457526C (en) Process for the production of arsenic-containing thioureas
DE954994C (en) Process for the production of complex protein compounds of the metal complexes of the chlorophyll and porphyrin series
DE947333C (en) Process for the production of crystallized islet hormone preparations
DE510437C (en) Process for the preparation of Benzimidazolonstibinsäuren